Managing ambulatory ulcerative colitis patients with infliximab: A long-term follow-up study in primary gastroenterology centers

European Journal of Internal Medicine

Volumn 25, Issue 8, 2014, Pages 757-761

  Tursi, Antonio ^a   Elisei, Walter ^b   Picchio, Marcello ^c   Penna, Antonio ^d   Lecca, Piera Giuseppina ^e   Forti, Giacomo ^f   Giorgetti, Gianmarco ^g   Faggiani, Roberto ^h   Zampaletta, Costantino ^h   Pelecca, Giorgio ^h   Brandimarte, Giovanni ^e  

^a ASL BAT   (Italy)

^b ASL Roma H   (Italy)

^c Hospital P Colombo   (Italy)

^d Ospedale San Paolo   (Italy)

^e Cristo Re Hospital   (Italy)

^f SANTA MARIA GORETTI HOSPITAL   (Italy)

^g S EUGENIO HOSPITAL   (Italy)

^h BELCOLLE HOSPITAL   (Italy)

Author keywords

Clinical practice; Clinical remission; Histological healing; Infliximab; Mucosal healing; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; COHORT ANALYSIS; COLON RESECTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INFUSION RELATED REACTION; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRURITUS; RECTUM CANCER; REMISSION; RETROSPECTIVE STUDY; ULCER HEALING; ULCERATIVE COLITIS; URTICARIA; CLINICAL TRIAL; COLITIS, ULCERATIVE; DISEASE COURSE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; STOMACH MUCOSA; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REMISSION INDUCTION; YOUNG ADULT;

EID: 84908214547     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2014.07.007     Document Type: Article

References (33)

1. A. Dignass, R. Eliakim, F. Magro, C. Maaser, Y. Chowers, and K. Geboes Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis J Crohn's Colitis 6 2012 965 990
2. A. Dignass, J.O. Lindsay, A. Sturm, A. Windsor, J.F. Colombel, and M. Allez Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management J Crohn's Colitis 6 2012 991 1030
3. G.R. Lichtenstein, M.T. Abreu, R. Cohen, W. Tremaine, and American Gastroenterological Association American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease Gastroenterology 130 2006 940 987
4. S. Travis, G. Van Assche, A. Dignass, E. Cabré, and M.A. Gassull On the second ECCO consensus on Crohn's disease J Crohn's Colitis 4 2010 1 6
5. G.R. D'Haens, R. Panaccione, P.D. Higgins, S. Vermeire, M. Gassull, and Y. Chowers The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 106 2011 199 212
6. A. Orlando, A. Armuzzi, C. Papi, V. Annese, S. Ardizzone, and L. Biancone The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) clinical practice guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease Dig Liver Dis 43 2011 1 20
7. J.B. Seidelin, M. Coskun, and O.H. Nielsen Mucosal healing in ulcerative colitis: pathophysiology and pharmacology Adv Clin Chem 59 2013 101 123
8. V. Villanacci, E. Antonelli, K. Geboes, G. Casella, and G. Bassotti Histological healing in inflammatory bowel disease: a still unfulfilled promise World J Gastroenterol 19 2013 968 978
9. P. Molander, T. Sipponen, H. Kemppainen, A. Jussila, T. Blomster, and R. Koskela Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD J Crohn's Colitis 7 2013 730 735
10. G. Bouguen, B.G. Levesque, S. Pola, E. Evans, and W.J. Sandborn Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis Inflamm Bowel Dis 20 2014 231 239
11. M.S. Silverberg, J. Satsangi, T. Ahmad, I.D. Arnott, C.N. Bernstein, and S.R. Brant Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology Can J Gastroenterol 19 Suppl. A 2005 5 36
12. F. Rizzello, P. Gionchetti, A. D'Arienzo, F. Manguso, G. Di Matteo, and V. Annese Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study Aliment Pharmacol Ther 16 2002 1109 1116
13. K.W. Schroeder, W.J. Tremaine, and D.M. Ilstrup Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomised study N Engl J Med 317 1987 1625 1629
14. K. Geboes, R. Riddell, A. Ost, B. Jensfelt, T. Persson, and R. Löfberg A reproducible grading scale for histological assessment of inflammation in ulcerative colitis Gut 47 2000 404 409
15. R. Panaccione, S. Ghosh, S. Middleton, J.R. Márquez, B.B. Scott, and L. Flint Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis Gastroenterology 146 2014 392 400
16. D. Parakkal, H. Sifuentes, R. Semer, and E.D. Ehrenpreis Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk Eur J Gastroenterol Hepatol 23 2011 1150 1156
17. P. Rutgeerts, W.J. Sandborn, B.G. Feagan, W. Reinisch, A. Olson, and J. Johanns Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476
18. M. Ferrante, S. Vermeire, H. Fidder, F. Schnitzler, M. Noman, and G. Van Assche Long-term outcome after infliximab for refractory ulcerative colitis J Crohn's Colitis 2 2008 219 225
19. Y. Gonzalez-Lama, I. Fernandez-Blanco, A. Lopez-SanRoman, C. Taxonera, B. Casis, and S. Tabernero Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response Hepatogastroenterology 55 2008 1609 1614
20. K.M. Lee, Y.T. Jeen, J.Y. Cho, J.S. Koo, D.I. Park, and J.P. Im Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis. A Korean multicenter retrospective study J Gastroenterol Hepatol 28 2013 829 1833
21. D. Laharie, J. Filippi, X. Roblin, S. Nancey, J.B. Chevaux, and X. Hébuterne Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience Aliment Pharmacol Ther 37 2013 998 1004
22. K. Yokoyama, K. Kobayashi, M. Mukae, M. Sada, and W. Koizumi Clinical study of the relation between mucosal healing and long-term outcomes in ulcerative colitis Gastroenterol Res Pract 2013 2013 192794
23. J.F. Colombel, P. Rutgeerts, W. Reinisch, D. Esser, Y. Wang, and Y. Lang Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis Gastroenterology 141 2011 1194 1201
24. A. Oussalah, L. Evesque, D. Lahaire, X. Roblin, G. Boschetti, and S. Nancey A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization Am J Gastroenterol 105 2010 2617 2625
25. B. Lemmens, I. Arjis, G. Van Assche, X. Sagaert, K. Geboes, and M. Ferrante Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis Inflamm Bowel Dis 19 2013 1194 1201
26. P. Molander, T. Sipponen, H. Kemppainen, A. Jussila, T. Blomster, and R. Koskela Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD J Crohn's Colitis 7 2013 730 735
27. J.E. Baars, V.J. Nuij, B. Oldenburg, E.J. Kuipers, and C.J. van der Woude Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation Inflamm Bowel Dis 18 2012 1634 1640
28. L. Rosenberg, K.S. Nanda, T. Zenlea, A. Gifford, G.O. Lawlor, and K.R. Falchuk Histologic markers of inflammation in patients with ulcerative colitis in clinical remission Clin Gastroenterol Hepatol 11 2013 991 996
29. J.A. Stolwijk, A.M. Langers, J.C. Hardwick, R.A. Veenendaal, H.W. Verspaget, and R.A. van Hogezand A thirty-year follow-up surveillance study for neoplasia of a Dutch ulcerative colitis cohort ScientificWorldJournal 2013 2013 274715
30. R. Lv, W. Qiao, Z. Wu, Y. Wang, S. Dai, and Q. Liu Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis PLoS ONE 9 2014 e86692
31. C.J. Williams, L. Peyrin-Biroulet, and A.C. Ford Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease Aliment Pharmacol Ther 39 2014 447 458
32. J.P. Gisbert, F. Gomollón, J. Hinojosa, and A. López San Román Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain J Crohn's Colitis 4 2010 567 574
33. Gruppo di lavoro OsMed L'uso dei farmaci in Italia. Rapporto nazionale anno 2010 2011 Il Pensiero Scientifico Editore Roma